Carbohydrate based vaccines. 2006

Johannes F G Vliegenthart
Bijvoet Center, Division Bioorganic Chemistry, Utrecht University, Padualaan 8, NL-3584 CH Utrecht, The Netherlands. j.f.g.vliegenthart@chem.uu.nl

In the past decades, a gradual increase in the resistance to antibiotics has been observed, leading to a serious thread for successful treatment of bacterial infections. This feature in addition to difficulties in developing adequate drugs against (tropical) diseases caused by parasites has stimulated the interest in vaccines to prevent infections. In principle, various types of cell surface epitopes, characteristic for the invading organism or related to aberrant growth of cells, can be applied to develop vaccines. The progress in establishing the structure of carbohydrate immuno-determinants in conjunction with improvements in carbohydrate synthesis has rendered it feasible to develop new generations of carbohydrate-based vaccines.

UI MeSH Term Description Entries
D002241 Carbohydrates A class of organic compounds composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n. The largest class of organic compounds, including STARCH; GLYCOGEN; CELLULOSE; POLYSACCHARIDES; and simple MONOSACCHARIDES. Carbohydrate
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D006001 Glycoconjugates Carbohydrates covalently linked to a nonsugar moiety (lipids or proteins). The major glycoconjugates are glycoproteins, glycopeptides, peptidoglycans, glycolipids, and lipopolysaccharides. (From Biochemical Nomenclature and Related Documents, 2d ed; From Principles of Biochemistry, 2d ed) Glycoconjugate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000954 Antigens, Surface Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated. Cell Surface Antigens,Surface Antigens,Surface Markers, Immunological,Cell Surface Antigen,Immunologic Surface Markers,Markers, Immunological Surface,Surface Antigen,Surface Markers, Immunologic,Antigen, Cell Surface,Antigen, Surface,Antigens, Cell Surface,Immunological Surface Markers,Markers, Immunologic Surface,Surface Antigen, Cell,Surface Antigens, Cell
D001428 Bacterial Vaccines Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. Bacterial Vaccine,Bacterin,Vaccine, Bacterial,Vaccines, Bacterial
D016052 Protozoan Vaccines Suspensions of attenuated or killed protozoa administered for the prevention or treatment of infectious protozoan disease. Vaccines, Protozoan
D019496 Cancer Vaccines Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. Cancer Vaccine,Neoplasm Vaccines,Tumor Vaccine,Tumor Vaccines,Vaccines, Cancer,Vaccines, Neoplasm,Vaccines, Tumor,Vaccine, Cancer,Vaccine, Tumor

Related Publications

Johannes F G Vliegenthart
January 2015, Methods in molecular biology (Clifton, N.J.),
Johannes F G Vliegenthart
January 2020, Advanced drug delivery reviews,
Johannes F G Vliegenthart
January 2015, Methods in molecular biology (Clifton, N.J.),
Johannes F G Vliegenthart
May 2018, Medicinal research reviews,
Johannes F G Vliegenthart
April 2013, Expert review of vaccines,
Johannes F G Vliegenthart
November 2010, Expert review of vaccines,
Johannes F G Vliegenthart
August 2005, Journal of pharmaceutical and biomedical analysis,
Johannes F G Vliegenthart
December 2020, Drug discovery today. Technologies,
Johannes F G Vliegenthart
December 2020, Drug discovery today. Technologies,
Johannes F G Vliegenthart
December 2004, Drug discovery today. Technologies,
Copied contents to your clipboard!